SCHEMBL29903147

SCHEMBL29903147

Oc1cc(Br)c2c(Br)cccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
DNMT1 P26358 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
MCL1 Q07820 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
NQO2 P16083 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 3/20 0.37
HSD17B10 Q99714 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
GAA P10253 2/20 0.37
INPPL1 O15357 1/20 0.37
NSD2 O96028 1/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23409296 1.00 ALDH1A1 (0.40) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL31049123 0.85 NQO2 (0.47) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL9234732 0.85 MEN1 (0.54) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL25323401 0.83 HSD17B10 (0.39) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL25352843 0.82 MEN1 (0.41) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL23053933 0.82 ESR1 (0.39) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL22208228 0.82 MEN1 (0.39) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL25308480 0.82 MEN1 (0.41) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL29418778 0.82 MEN1 (0.39) ALDH1A1MEN1KMT2ADNMT1CACNA1B
SCHEMBL26708991 0.82 ALDH1A1 (0.36) ALDH1A1MEN1KMT2ADNMT1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118900837-A 5,6,7, 8-Tetrahydro-2, 6-naphthyridine derivatives as cancer therapeutic agents 弗赖斯治疗公司 2024-11-05 CN disclosed
CN-115003677-B Compounds having inhibitory activity against KRAS G12D mutations 大鹏药品工业株式会社 2024-08-27 CN disclosed
CN-117769554-A Small molecule inhibitors of KRAS muteins 大鹏药品工业株式会社 2024-03-26 CN disclosed
CN-116801883-A Heteroaromatic ring compounds, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2023-09-22 CN disclosed
WO-2023125627-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF LYNK PHARMACEUTICALS CO., LTD. (CN) 2023-07-06 WO disclosed
CN-115850267-A Bridged ring compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2023-03-28 CN disclosed
EP-4065583-A1 A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION Taiho Pharmaceutical Co., Ltd. (JP) 2022-10-05 EP disclosed
CN-115003677-A Compounds having inhibitory activity against KRAS G12D mutation 大鹏药品工业株式会社 2022-09-02 CN disclosed